



# LKT Laboratories, Inc.

## Abemaciclib mesylate

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

### Product Information

**Product ID** A044178

**CAS No.** 1231930-82-7

**Chemical Name** N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine methanesulfonate

**Synonym** LY2835219 methanesulfonate

**Formula** C<sub>27</sub>H<sub>32</sub>F<sub>2</sub>N<sub>8</sub> • CH<sub>4</sub>O<sub>3</sub>S

**Formula Wt.** 602.71

**Melting Point**


**Purity** ≥98%

**Solubility** DMSO:84 mg/mL;  
Water:100 mg/mL

**Store Temp** -20° C

**Ship Temp** Blue Ice

**Description** Abemaciclib is a CDK4 and CDK6 inhibitor found to inhibit retinoblastoma phosphorylation, leading to G1/S arrest in ER+ breast cancer cells and to promote metabolic alterations in metastatic HR+ breast cancer cells.



**Bulk quantities available upon request**

Product ID	Size
A044178	25 mg
A044178	50 mg
A044178	100 mg

**References** Torres-Guzman R, Calsina B, Hermoso A, et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. *Oncotarget*. 2017 May 10. Epub ahead of print. PMID: 28537883

Tate SC, Burke TF, Hartman D, et al. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. *Br J Cancer*. 2016 Mar 15;114(6):669-679. PMID: 26978007

Knudsen ES, Hutcheson J, Vail P, et al. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. *Oncotarget*. 2017 Jun 10. Epub ahead of print. PMID: 28620137

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.